In 2016, the World Health Organization (WHO) recognized four distinct entities of anaplastic large cell lymphoma (ALCL) including ALK-negative primary cutaneous ALCL, breast implant-associated ALCL, systemic ALK-negative (ALK(–)) or ALK-positive (ALK(+)) ALCL. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.